is tirzepatide a glp-1 receptor agonist (LY3298176) Dual GIP and for Type 2 Diabetes Research Comparing GLP-type therapies for weight
Description
For best results, we recommend 3-6 months of consistent daily use
95% CI 0.94, 1.03)
Discover dual vs
A comprehensive phase 3 program is ongoing to evaluate efficacy, safety, and cardiovascular/renal outcomes in people with obesity and/or T2D
95% CI 0.35, 3.14)
